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Abstract  29 
Objective  30 
Identification of germline mutation in patients with apparently sporadic phaeochromocytomas 31 
and paragangliomas is crucial. Clinical indicators, which include young age, bilateral or 32 
multifocal, extra-adrenal, malignant or recurrent tumours, predict the likelihood of harbouring 33 
germline mutation in Caucasian subjects. However, data on the prevalence of germline 34 
mutation, as well as the applicability of these clinical indicators in Chinese, are lacking. 35 
 36 
Design and methods 37 
We conducted a cross-sectional study at a single endocrine tertiary referral centre in Hong 38 
Kong. Subjects with phaeochromocytomas and paragangliomas were evaluated for the 39 
presence of germline mutations involving 10 susceptibility genes, which included NF1, RET, 40 
VHL, SDHA, SDHB, SDHC, SDHD, TMEM 127, MAX and FH genes. Clinical indicators 41 
were assessed for their association with the presence of germline mutations.  42 
 43 
Results 44 
Germline mutations, two being novel, were found in 24.4% of the 41 Chinese subjects 45 
recruited and 11.4% among those with apparently sporadic presentation. The increasing 46 
number of the afore-mentioned clinical indicators significantly correlated with the likelihood 47 
of harbouring germline mutation in one of the 10 susceptibility genes. (r = 0.757, p = 0.026). 48 
The presence of 2 or more clinical indicators should prompt genetic testing for germline 49 
mutations in Chinese subjects. 50 
 51 
Conclusions 52 
In conclusion, our study confirmed that a significant proportion of Chinese subjects with 53 
apparently sporadic phaeochromocytoma and paraganglioma harboured germline mutations 54 
and these clinical indicators identified from Caucasians series were also applicable in Chinese 55 
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subjects. This information will be of clinical relevance in the design of appropriate genetic 56 
screening strategies in Chinese populations. 57 
 58 
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 4 
Introduction 84 
The 2014 Endocrine Society Clinical Practice Guideline for phaeochromocytoma and 85 
paraganglioma (PPGL) focuses on the multidisciplinary yet personalized management of 86 
PPGLs. In particular, the guideline reflects a major paradigm shift in the clinical management 87 
of these traditional “10% tumours”, by recommending that genetic testing be considered in 88 
each patient with PPGL, especially those with bilateral, malignant, or extra-adrenal disease, 89 
even if they do not have a positive family history of PPGL [1]. These recommendations have 90 
certainly recognized the increased prevalence of germline mutations among patients with 91 
PPGL, as well as the distinct genotype-phenotype correlations in hereditary PPGL syndromes, 92 
which could impact on the therapeutic approach for the disease, especially in metastatic 93 
PPGLs 2. 94 
 95 
To date, more than 14 susceptibility genes have been identified that are implicated in the 96 
pathogenesis of PPGL, accounting for a prevalence of approximately 40% of hereditary 97 
PPGLs as reported from Caucasian series [3]. However, the prevalence of germline mutations 98 
among patients with apparently sporadic PPGLs (i.e. absence of positive family history of 99 
PPGL or features suggestive of hereditary PPGL syndromes) is lower. In a recent systematic 100 
review of 31 studies, which involved 5031 subjects mostly from European populations, the 101 
prevalence of germline mutations was around 11-13%, if only apparently sporadic PPGLs 102 
were included in the analysis [4]. Nonetheless, although with much geographical variations, 103 
studies on the overall prevalence of germline mutations among apparently sporadic PPGLs 104 
are mostly from Caucasian populations. On the other hand, comprehensive genetic study in 105 
Chinese with apparently sporadic PPGLs is lacking [5-7]. Previous genetic studies in Chinese 106 
subjects with PPGL were either limited to one single susceptibility gene or to head and neck 107 
paragangliomas only [8-10]. Furthermore, until next generation sequencing (NGS) becomes 108 
readily available, universal screening of all subjects with PPGL remains a laborious process. 109 
In fact, even if NGS gains favour in future as a cost-effective and efficient method of genetic 110 
screening in PPGL [11], there are still shortcomings and technical limitations with NGS [12]. 111 
 5 
Therefore, various algorithms have been developed from Caucasian series in order to 112 
prioritize the screening of different susceptibility genes on the basis of clinical indicators, 113 
which include age at disease presentation and different tumour characteristics [13]. However, 114 
the applicability of these clinical indicators to predict the presence of germline mutations in 115 
Chinese patients with apparently sporadic PPGLs is still not known.  116 
 117 
Therefore, we conducted this study to examine the genetics of Chinese patients with 118 
apparently sporadic PPGLs at a tertiary endocrine referral centre in Hong Kong. Our study 119 
evaluated the local prevalence of germline mutations in 10 susceptibility genes of PPGL: the 120 
neurofibromin 1 (NF1) tumour suppressor gene in neurofibromatosis type 1; the rearranged 121 
during transfection (RET) proto-oncogene; the von Hippel-Lindau (VHL) tumour suppressor 122 
gene, genes encoding the four subunits (A, B, C and D) of the succinate dehydrogenase 123 
(SDH) complex (SDHA, SDHB, SDHC and SDHD); the transmembrane protein 127 (TMEM 124 
127) gene, the MYC-associated factor X (MAX) tumour suppressor gene and the fumurate 125 
hydratase (FH) genes. We also analysed the application of the 5 generally agreed clinical 126 
indicators for the presence of germline mutation in these subjects: age at disease onset 127 
younger than 45 years old, bilateral or multifocal disease, extra-adrenal involvement, and 128 
having recurrent, or malignant tumours.  129 
 130 
Materials and methods  131 
This was a cross-sectional study involving subjects with PPGL managed at the Queen Mary 132 
Hospital in Hong Kong. The study protocol was approved by the institutional review board of 133 
the University of Hong Kong / Hospital Authority Hong Kong West Cluster. 134 
 135 
In the study, the 2004 World Health Organization (WHO) definition of PPGL was applied 14. 136 
Phaeochromocytoma is defined as a tumour arising from catecholamine-producing 137 
chromaffin cells in the adrenal medulla, while closely related tumour of extra-adrenal 138 
sympathetic and parasympathetic paraganglia is classified as paraganglioma [15]. Diagnoses 139 
 6 
of PPGL were based on urinary levels of catecholamines or catecholamine metabolites 140 
(including normetanephrines, metanephrines, vanillylmandelic acid and homovanillic acid) 141 
and surgical histology, with or without iodine 131-labelled metaiodobenzylguanidine 142 
scintigraphy (MIBG). Head and neck paraganglioma was diagnosed on the basis of imaging 143 
findings (computed tomography, magnetic resonance imaging or ultrasonography, as 144 
appropriate) or surgical histology [16]. Malignancy was defined based on the WHO 145 
classification, as the presence of frank loco-regional invasion or metastases to non-chromaffin 146 
sites [17].  147 
 148 
In the study, apparently sporadic presentation was defined as the absence, at disease 149 
presentation, of a family history of PPGL, or syndromic features (personal history of 150 
medullary thyroid carcinoma or oral mucosal neuromas, or haemangioblastoma at disease 151 
presentation, or phenotypic features of neurofibromatosis type 1), which were suggestive of 152 
multiple endocrine neoplasia (MEN) type 2, von Hippel Lindau (VHL) disease or 153 
neurofibromatosis type 1 (NF1), respectively.  154 
 155 
All subjects with PPGL from the medical and surgical endocrine clinics of Queen Mary 156 
Hospital were invited to participate in this study from March 2011 to December 2012. In 157 
known familial cases of PPGL, only the probands were included.  158 
 159 
Among a total of 60 subjects with PPGLs being followed up at our clinics, 11 known 160 
asymptomatic germline mutations carriers were excluded, as they were family members of 161 
probands with familial diseases (10 subjects with MEN2, and 1 subject with VHL disease). 162 
Of the remaining 49 subjects, 8 refused to participate. Therefore, 41 unrelated eligible 163 
subjects with PPGLs were finally enrolled into our study. 164 
 165 
Demographic and clinical data were collected from the computer-based clinical management 166 
system of the Queen Mary Hospital, and through reviewing their medical records. Except for 167 
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probands in familial cases with known germline mutations, all recruited subjects underwent 168 
genetic testing for germline mutations involving all coding exons of FH, MAX, SDHA, SDHB, 169 
SDHC, SDHD, TMEM127, VHL genes and exons 10, 11 and 16 of RET genes. 170 
Neurofibromatosis type 1 was diagnosed on the basis of phenotype alone as generally 171 
accepted [18]. All subjects gave written informed consent prior to any study related 172 
procedures. 173 
 174 
Genomic DNA samples were extracted from 10ml ethylenediaminetetraacetic acid (EDTA) 175 
peripheral whole blood using the QIAamp DNA mini kit (QIAGEN, Hilden, Germany) 176 
according to the manufacturer’s instructions. Forward and reverse primers were designed 177 
based on previously published information [16, 19-24]. All coding exons and exon-intron 178 
boundaries of FH, MAX, SDHA, SDHB, SDHC, SDHD, TMEM127, VHL genes and exons 10, 179 
11 and 16 of RET gene were screened for mutations by Sanger sequencing, using an ABI 180 
3730xl DNA analyser (Life Technologies, USA) at the Centre for Genomic Sciences, the 181 
University of Hong Kong. The sequence results were analysed with the ABI Sequence 182 
Scanner Software v1.0 (Life Technologies, USA). In-silico analysis was used for the 183 
assessment of their pathogenicity. Prediction software modules used for in-silico analysis 184 
included Mutation Taster (http://www.mutationtaster.org/), PolyPhen-2 185 
(http://genetics.bwh.harvard.edu/pph2/) and KGGSeq 186 
(http://statgenpro.psychiatry.hku.hk/limx/kggseq/). Furthermore, a control group of DNA 187 
samples from 100 healthy Hong Kong Chinese subjects from the Hong Kong Cardiovascular 188 
Risk Factor Prevalence Study (CRISPS) cohort [25] was used as reference samples for 189 
population allele frequency estimation in the evaluation of novel missense variants. 190 
 191 
All data were analysed with SPSS Statistics Version 20.0 (SPSS, Chicago, IL). Descriptive 192 
statistics were calculated for all variables. Comparison of categorical data was performed by 193 
Chi-squared test or Fisher’s exact test as appropriate. Continuous data were compared using 194 
Mann-Whitney-U test. Ordinal data were analysed using the Gamma test. Logistic regression 195 
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models were used to evaluate the association among various clinical parameters with the 196 
likelihood of subject harbouring germline mutations. Receiver operating characteristic (ROC) 197 
curve was used to evaluate the optimal number of clinical indicators in our study cohort to 198 
indicate the presence of germline mutation. Optimal cut-off was derived from Youden index 199 
criterion [maximum of (sensitivity + specificity) - 1] [26]. All tests were two-sided, and p 200 
value of less than 0.05 was considered statistically significant. 201 
 202 
Results 203 
In our cohort of 41 subjects, 9 subjects were found to harbour germline mutations and 1 204 
subject had NF1, which translated into a prevalence of 24.4% for hereditary PPGL. On the 205 
other hand, 6 of these 10 subjects had syndromic features suggestive of hereditary disease at 206 
disease presentation. Therefore, 35 subjects had PPGL with apparently sporadic presentation, 207 
and the prevalence rate of germline mutations was 11.4% (4 of 35 subjects). 208 
 209 
Among the 9 mutations identified on sequencing, 7 were located on the RET gene, 1 on the 210 
SDHB gene and 1 on the SDHD gene. Both the deletion mutation in the SDHB gene and the 211 
insertion mutation on the SDHD gene were novel pathogenic variants that had not been 212 
previously reported (Table 1). A sequence variant was also found on exon 2 of the TMEM127 213 
(c.53C>T) gene in 3 subjects, including the subject with an SDHB germline mutation. All 3 214 
subjects were heterozygous for this sequence variant. However, in-silico analyses suggested 215 
that the sequence variant was not associated with any change in protein structure. 216 
Furthermore, screening of 100 healthy controls also revealed 2 subjects with the same 217 
heterozygous variants, yielding a minor allelic frequency of 1%. Hence, this sequence variant 218 
in TMEM127 gene was likely a polymorphism rather than a pathogenic mutation. 219 
 220 
Of the 35 subjects (18 men and 17 women) with apparently sporadic PPGL in our study 221 
cohort, 27 and 8 had phaeochromocytoma and paraganglioma respectively. Among those 222 
paragangliomas, 1 was head and neck paraganglioma, 3 were in the abdomen and 4 were in 223 
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the bladder. Their mean age of diagnosis was 45 ± 13 years. Other biochemical and tumour 224 
characteristics are summarized in Table 2. About 77% of the tumours were larger than 3cm, 225 
28.6% were either multifocal or bilateral tumours, and 89.3% showed avidity on MIBG scan. 226 
The prevalence of malignancy was 11.4% and the recurrence rate was 22.9% over a median 227 
follow-up of 5 years.  228 
 229 
In our study, the frequency of germline mutations in subjects with syndromic presentation (4 230 
subjects with a personal history of medullary thyroid carcinoma or oral mucosal neuromas, 1 231 
subject with a family history of PPGL and 1 subject with phenotypic features of NF1) was 232 
100%. However, in those subjects with apparently sporadic presentation, we found that only 233 
“age of disease onset younger than 45 years old” (p = 0.023) and having “bilateral or 234 
multifocal tumours” (100% versus 19% in subjects without mutations, p <0.004) were 235 
statistically significant clinical indicators of presence of germline mutations (Table 3). 236 
Furthermore, we have shown that, with an increasing number of these clinical indicators, the 237 
subjects were more likely to harbour germline mutations (r = 0.757, p = 0.026; Gamma test). 238 
In addition, with the ROC curve, we demonstrated that in those subjects with an apparently 239 
sporadic presentation of PPGL, the presence of 2 or more of the clinical indicators provided 240 
the optimal cut-off to initiate genetic testing, with a 100% sensitivity of picking up germline 241 
mutation in 1 of the 10 susceptibility genes of PPGL, coupled with a specificity of 77.4%. 242 
The area under the curve was 0.85 (95% CI = 0.72-0.99) (Figure 1).  243 
 244 
Discussions and conclusions 245 
Our study is the first comprehensive series studying the prevalence of germline mutation 246 
involving a substantial number of susceptibility genes in Chinese subjects with apparently 247 
sporadic PPGLs. Since 2002, there have been several Caucasian studies on the prevalence of 248 
hereditary PPGL [16, 27-29], although their results differed owing to geographical variations, 249 
differences in inclusion and exclusion criteria, and the number of susceptibility genes being 250 
studied. Our group demonstrated that the prevalence of germline mutation in Chinese subjects 251 
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with apparently sporadic PPGL was in keeping with published Caucasian data, and the 252 
previous notion that only 10% of PPGLs were hereditary was no longer valid worldwide. 253 
Given the rapid advancement in molecular biology, and the fact that known germline 254 
mutations are still not detected in a significant proportion of familial PPGL cases worldwide, 255 
it is anticipated that the prevalence of germline mutations in PPGLs, including in Hong Kong, 256 
may be higher and will likely continue to rise in the future.  257 
 258 
Furthermore, in this study, we have demonstrated that the 5 generally agreed clinical 259 
indicators for the presence of germline mutation in Caucasian patients with apparently 260 
sporadic PPGLs: age at disease onset younger than 45 years old, bilateral or multifocal 261 
disease, extra-adrenal involvement, and having recurrent, or malignant tumours, were also 262 
applicable in the clinical assessment in Chinese populations. Although in our cohort, only 263 
“age younger than 45 years old” and “bilateral or multifocal disease” were significant clinical 264 
indicators in univariate analysis, we did show that with an increasing number of these clinical 265 
indicators, Chinese subjects with apparently sporadic PGLL were more likely to harbour 266 
germline mutations in 1 of the 10 susceptibility genes examined. In other words, our findings 267 
were in line with the recommendations of the 2014 Endocrine Society Clinical Practice 268 
Guideline for PPGL, which recommended that genetic testing should be considered in each 269 
patient with PPGL, especially those with bilateral, malignant, or extra-adrenal disease, even if 270 
they do not have a positive family history of PPGL. In fact, subjects with a family history of 271 
PPGL or a personal history of syndromic lesions (e.g. medullary thyroid carcinoma or VHL 272 
disease associated tumours) should inevitably be offered genetic testing of the corresponding 273 
specific gene. Nonetheless, after-all, the majority of PPGLs are still sporadic tumours without 274 
a positive family history. In addition, hereditary diseases could have been missed, due to de 275 
novo mutations, genomic imprinting, unexhausted family history, and incomplete disease 276 
penetrance [30]. However, the list of susceptibility genes of PPGL is anticipated to keep 277 
growing, whilst universal screening of all PPGL subjects for all susceptibility genes is still 278 
technically or financially not feasible in most countries. Before NGS or whole exome 279 
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sequencing becomes a widely accessible genetic screening method at a reasonable cost, our 280 
findings might perhaps provide an alternative algorithm to guide targeted genetic testing in 281 
Chinese patients with apparently sporadic PPGL. In our cohort, we found that genetic testing 282 
was clearly indicated in Chinese subjects with 2 or more of the afore-mentioned clinical 283 
indicators. With this, the sensitivity of picking up a germline mutation in a Chinese subject 284 
with apparently sporadic PPGL was 100%, and the specificity was 74.2%. These translated to 285 
a positive predictive value of 33.3% and a negative predictive value of 100%. Since 286 
phaeochromocytoma carries significant mortality if they are not diagnosed early and properly 287 
treated 31, there is no doubt that the detection of a germline mutation would pose a significant 288 
impact on both disease management and tumour surveillance of not only the index patient, but 289 
also their as yet unaffected family member. With a sensitivity and negative predictive value 290 
up to 100%, the risk of missing a hereditary PPGL could certainly be minimized.  291 
 292 
Our study has several limitations. First, referral bias exists as this study was carried out at a 293 
tertiary referral centre, and patients with more difficult tumours, for example extra-adrenal 294 
and mulifocal involvement, or malignant or recurrent disease might get referred and hence 295 
increased the likelihood of having subjects potentially harbouring germline mutations. 296 
However, this is not entirely true, as more than 50% of subjects in our cohort suffered from 297 
isolated unilateral benign phaeochromocytomas only. Nonetheless, even if significant referral 298 
bias does exist, this might perhaps further justify the use of a targeted approach in genetic 299 
testing, as universal screening in Chinese patients with apparently sporadic PPGL is unlikely 300 
to have added benefits, assuming an even lower prevalence of germline mutations outside our 301 
study cohort. On the other hand, the prevalence of germline mutations in our cohort could 302 
also have been underestimated, as evaluation of other known susceptibility genes of PPGL 303 
(the gene encoding SDH assembly factor 2 [SDHAF2] [32], the hypoxia inducible factor 2A 304 
[HIF2A] gene [33], the kinesin family member 1B [KIF1Bβ] gene [34] and the propyl-305 
hydroxylase domain 2 [PHD2] gene [35]) were not included in our current study. However, in 306 
a recent study involving 68 subjects with apparently sporadic PPGLs, there was only 1 subject 307 
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each positive for germline mutation of KIF1Bβ and PHD2 genes respectively, suggesting the 308 
rarity of these germline mutations [36]. HIF2A mutations are usually found as sporadic 309 
mutations in tumour samples [33]. Furthermore, SDHAF2 germline mutations are often 310 
associated with multiple head and neck paragangliomas3 and there were only 2 subjects with 311 
head and neck paraganglioma in our cohort with one of them already found to be positive for 312 
SDHD germline mutation. In fact, the few head and neck paragangliomas included in our 313 
study cohort is also one of the main limitations in this study such that a more comprehensive 314 
review covering all types of PPGL in Hong Kong is not possible. Other limitations include 315 
the relatively short duration of follow-up in this study. As malignant tumours might occur 316 
many years after surgery of the primary PPGL, with a median follow-up of 5 years in this 317 
study, the prevalence of malignancy could also have been under-estimated. Furthermore, in 318 
our study, measurement of calcitonin level was not required when defining “apparently 319 
sporadic presentation” in the study subjects. Indeed, in places where genetic testing is not 320 
readily available, calcitonin measurement is useful, especially in the context of young patients 321 
presenting with bilateral phaeochromocytomas. However, given that calcitonin assays are not 322 
always reliable, genetic testing should remain the gold standard in the evaluation, especially 323 
when serum calcitonin level is equivocal. Last but not least, the relatively small sample size in 324 
our study rendered more detailed analysis of genotype-phenotype correlations in these 325 
germline mutations not possible. In fact, the biochemical profile is one of the major 326 
discriminants for prioritizing the genetic testing. However, this prioritization of genetic 327 
testing was not carried out in our study and hence we were also unable to address the issue of 328 
cost effectiveness.  329 
 330 
Nonetheless, this is the first study on genetic screening and the applicability of clinical 331 
indicators predicting germline mutations in a Chinese population with apparently sporadic 332 
PPGL, covering a significant number of causative genes in this disease. More extensive 333 
research involving a larger cohort of Chinese subjects is definitely warranted to further 334 
characterize the genetics of this disease in our population. 335 
 13 
 336 
Declaration of interest 337 
My co-authors and I declare no conflicts of interest.  338 
 339 
Author contributions. 340 
C.H.L. researched the data and wrote the manuscript. W.S.C, Y.C.W., C.Y.Y., and B.H.H.L. 341 
researched the data. C.H.Y.F. performed statistical analyses. C.Y.Y.C., K.H.M.K., S.P.L.C. 342 
and C.M.M. performed genetic analyses. K.C.B.T. critically reviewed and edited the 343 
manuscript. K.S.L.L. initiated and supervised the study, critically reviewed and edited the 344 
manuscript, and is the guarantor of this work and as such had full access to all the data in the 345 
study and takes responsibility for the integrity of the data and the accuracy of the data 346 
analysis 347 
 348 
Acknowledgments. 349 
We thank Ms. Rachel Wong for her technical assistance in genetics testing.  350 
This work was supported by a grant from the Training and Research Assistance Scheme of 351 
the Queen Mary Hospital Charitable Trust (TRAS 110-07 [01/13/124]). 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 14 
 364 
References 365 
 366 
1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, 367 
Murad MH, Naruse M, Pacak K, Young WF, Jr. & Endocrine S. 368 
Pheochromocytoma and paraganglioma: an endocrine society clinical practice 369 
guideline. J Clin Endocrinol Metab 2014; 99: 1915-1942 370 
2. Matro J, Giubellino A & Pacak K. Current and Future Therapeutic 371 
Approaches for Metastatic Pheochromocytoma and Paraganglioma: Focus on 372 
SDHB Tumors. Horm Metab Res 2013; 45: 147-153 373 
3. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from 374 
genetic heterogeneity. Nat Rev Cancer 2014; 14: 108-119 375 
4. Brito JP, Asi N, Bancos I, Gionfriddo MR, Zeballos-Palacios CL, Leppin AL, 376 
Undavalli C, Wang Z, Domecq JP, Prustsky G, Elraiyah TA, Prokop LJ, 377 
Montori VM & Murad MH. Testing for germline mutations in sporadic 378 
pheochromocytoma/paraganglioma: a systematic review. Clin Endocrinol 379 
(Oxf) 2014; 82: 338-345 380 
5. Tong AL, Zeng ZP, Yang D, Li HZ & Li M. Clinical analysis of 25 patients 381 
with bilateral pheochromocytomas. Zhonghua Nei Ke Za Zhi 2005; 44: 751-382 
754. 383 
6. Sun HY, Cui B, Su DW, Jin XL, Sun FK, Zu Y, Jiang L, Wang WQ & Ning 384 
G. LOH on chromosome 11q, but not SDHD and Men1 mutations was 385 
frequently detectable in Chinese patients with pheochromocytoma and 386 
paraganglioma. Endocrine 2006; 30: 307-312. 387 
7. Zhang B, Wang YM, Wang N, Ha XQ, Dong YC & Zhou DH. Genetic 388 
detection and analysis of the VHL gene in patients with sporadic 389 
pheochromocytoma. Zhonghua Zhong Liu Za Zhi 2009; 31: 361-365. 390 
8. Lo CY, Wat NM, Lam KY, Tiu SC, Chan J & Lam KS. Multiple endocrine 391 
neoplasia type 2A in Chinese families. Clin Endocrinol (Oxf) 2003; 58: 528. 392 
9. Qi XP, Chen XL, Ma JM, Du ZF, Fei J, Yang CP, Cheng J, Song QZ, Han JS, 393 
Jin HY, Chen ZG, Wang JQ, Yang YP, Ying RB, Liu WT, Zhao Y, Chen CY, 394 
Ke HP & Zhang XN. RET Proto-oncogene Genetic Screening of Families with 395 
Multiple Endocrine Neoplasia Type 2 Optimizes Diagnostic and Clinical 396 
Management in China. Thyroid 2012. (Epub ahead of print) 397 
10. Zheng X, Wei S, Yu Y, Xia T, Zhao J, Gao S, Li Y & Gao M. Genetic and 398 
clinical characteristics of head and neck paragangliomas in a Chinese 399 
population. Laryngoscope 2012; 122: 1761-1766. 400 
11. McInerney-Leo AM, Marshall MS, Gardiner B, Benn DE, McFarlane J, 401 
Robinson BG, Brown MA, Leo PJ, Clifton-Bligh RJ & Duncan EL. Whole 402 
exome sequencing is an efficient and sensitive method for detection of 403 
germline mutations in patients with phaeochromcytomas and paragangliomas. 404 
Clin Endocrinol (Oxf) 2014; 80: 25-33. 405 
12. Toledo RA & Dahia PL. Next-generation sequencing for the genetic screening 406 
of phaeochromcytomas and paragangliomas: riding the new wave, but with 407 
caution. Clin Endocrinol (Oxf) 2014; 80: 23-24. 408 
13. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, 409 
Mussig K, Muresan M, Schaffler A, Reisch N, Schott M, Fassnacht M, 410 
Opocher G, Klose S, Fottner C, Forrer F, Plockinger U, Petersenn S, 411 
Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz MK, Eng C & 412 
 15 
Neumann HP. Clinical predictors and algorithm for the genetic diagnosis of 413 
pheochromocytoma patients. Clin Cancer Res 2009; 15: 6378-6385. 414 
14. DeLellis RA LR, Heitz PU, Eng C. World Health Organization Classification 415 
of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC 416 
Press: Lyon. 2004. 417 
15. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, 418 
Grossman AB, Kimura N, Mannelli M, McNicol AM & Tischler AS. 419 
Pheochromocytoma: recommendations for clinical practice from the First 420 
International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 421 
2007; 3: 92-102. 422 
16. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, 423 
Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith 424 
WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz 425 
MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, 426 
Maier-Woelfle M, Peczkowska M, Szmigielski C & Eng C. Germ-line 427 
mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 428 
1459-1466. 429 
17. de Wailly P, Oragano L, Rade F, Beaulieu A, Arnault V, Levillain P & 430 
Kraimps JL. Malignant pheochromocytoma: new malignancy criteria. 431 
Langenbecks Arch Surg 2012; 397: 239-246. 432 
18. Neurofibromatosis. Conference statement. National Institutes of Health 433 
Consensus Development Conference. Arch Neurol 1988; 45: 575-578. 434 
19. Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, 435 
Nakamura S, Moriyama M & Shuin T. Detection of circulating cancer cells 436 
with von hippel-lindau gene mutation in peripheral blood of patients with 437 
renal cell carcinoma. Clin Cancer Res 2000; 6: 3817-3822. 438 
20. Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, 439 
McLeod DR, Yee HA, Brackmann DE, Slattery WH, 3rd, Myers EN, Ferrell 440 
RE & Rubinstein WS. Prevalence of SDHB, SDHC, and SDHD germline 441 
mutations in clinic patients with head and neck paragangliomas. J Med Genet 442 
2002; 39: 178-183. 443 
21. Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, Jouanno E, 444 
Jeunemaitre X, Benit P, Tzagoloff A, Rustin P, Bertherat J, Favier J & 445 
Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing 446 
paraganglioma. Hum Mol Genet 2010; 19: 3011-3020. 447 
22. Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil 448 
N, Inglada-Perez L, de Cubas AA, Amar L, Barontini M, de Quiros SB, 449 
Bertherat J, Bignon YJ, Blok MJ, Bobisse S, Borrego S, Castellano M, 450 
Chanson P, Chiara MD, Corssmit EP, Giacche M, de Krijger RR, Ercolino T, 451 
Girerd X, Gomez-Garcia EB, Gomez-Grana A, Guilhem I, Hes FJ, Honrado E, 452 
Korpershoek E, Lenders JW, Leton R, Mensenkamp AR, Merlo A, Mori L, 453 
Murat A, Pierre P, Plouin PF, Prodanov T, Quesada-Charneco M, Qin N, 454 
Rapizzi E, Raymond V, Reisch N, Roncador G, Ruiz-Ferrer M, Schillo F, 455 
Stegmann AP, Suarez C, Taschin E, Timmers HJ, Tops CM, Urioste M, 456 
Beuschlein F, Pacak K, Mannelli M, Dahia PL, Opocher G, Eisenhofer G, 457 
Gimenez-Roqueplo AP & Robledo M. MAX mutations cause hereditary and 458 
sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012; 18: 459 
2828-2837. 460 
23. Castro-Vega LJ, Buffet A, De Cubas AA, Cascon A, Menara M, Khalifa E, 461 
Amar L, Azriel S, Bourdeau I, Chabre O, Curras-Freixes M, Franco-Vidal V, 462 
Guillaud-Bataille M, Simian C, Morin A, Leton R, Gomez-Grana A, Pollard 463 
PJ, Rustin P, Robledo M, Favier J & Gimenez-Roqueplo AP. Germline 464 
 16 
mutations in FH confer predisposition to malignant pheochromocytomas and 465 
paragangliomas. Hum Mol Genet 2014; 23: 2440-2446. 466 
24. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, Toledo RA, 467 
Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacche M, Mendola A, Taschin 468 
E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater 469 
CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, 470 
Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M & 471 
Dahia PL. Spectrum and prevalence of FP/TMEM127 gene mutations in 472 
pheochromocytomas and paragangliomas. JAMA 2010; 304: 2611-2619. 473 
25. Wat NM, Lam TH, Janus ED & Lam KS. Central obesity predicts the 474 
worsening of glycemia in southern Chinese. Int J Obes Relat Metab Disord 475 
2001; 25: 1789-1793. 476 
26. Perkins NJ & Schisterman EF. The inconsistency of "optimal" cutpoints 477 
obtained using two criteria based on the receiver operating characteristic 478 
curve. Am J Epidemiol 2006; 163: 670-675. 479 
27. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre 480 
O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, 481 
Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, 482 
Jeunemaitre X & Gimenez-Roqueplo AP. Genetic testing in 483 
pheochromocytoma or functional paraganglioma. J Clin Oncol 2005; 23: 484 
8812-8818. 485 
28. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacche M, Mori L, Pignataro 486 
V, Bernini G, Giache V, Bacca A, Biondi B, Corona G, Di Trapani G, 487 
Grossrubatscher E, Reimondo G, Arnaldi G, Giacchetti G, Veglio F, Loli P, 488 
Colao A, Ambrosio MR, Terzolo M, Letizia C, Ercolino T & Opocher G. 489 
Clinically guided genetic screening in a large cohort of italian patients with 490 
pheochromocytomas and/or functional or nonfunctional paragangliomas. J 491 
Clin Endocrinol Metab 2009; 94: 1541-1547. 492 
29. Persu A, Lannoy N, Maiter D, Mendola A, Montigny P, Oriot P, Vinck W, 493 
Garin P, Hamoir M & Vikkula M. Prevalence and spectrum of SDHx 494 
mutations in pheochromocytoma and paraganglioma in patients from Belgium: 495 
an update. Horm Metab Res 2012; 44: 349-353. 496 
30. Benn DE & Robinson BG. Genetic basis of phaeochromocytoma and 497 
paraganglioma. Best Pract Res Clin Endocrinol Metab 2006; 20: 435-450. 498 
31. Prejbisz A, Lenders JW, Eisenhofer G & Januszewicz A. Mortality associated 499 
with phaeochromocytoma. Horm Metab Res 2013; 45: 154-158. 500 
32. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, 501 
Devilee P, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, 502 
Kremer H & Rutter J. SDH5, a gene required for flavination of succinate 503 
dehydrogenase, is mutated in paraganglioma. Science 2009; 325: 1139-1142. 504 
33. Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, 505 
Stratakis CA, Prchal JT & Pacak K. Somatic HIF2A gain-of-function 506 
mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367: 922-507 
930. 508 
34. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, 509 
Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look 510 
AT, Meyerson M, Peeper DS, Carter BD & Kaelin WG, Jr. The kinesin 511 
KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 512 
1p36 tumor suppressor. Genes Dev 2008; 22: 884-893. 513 
35. Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, 514 
Feunteun J, Pouyssegur J, Richard S & Gardie B. PHD2 mutation and 515 
 17 
congenital erythrocytosis with paraganglioma. N Engl J Med 2008; 359: 2685-516 
2692. 517 
36. Welander J, Andreasson A, Juhlin CC, Wiseman RW, Backdahl M, Hoog A, 518 
Larsson C, Gimm O & Soderkvist P. Rare germline mutations identified by 519 
targeted next-generation sequencing of susceptibility genes in 520 
pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2014; 99: 521 
E1352-1360. 522 
 523 
 524 
Figure legends 525 
Figure 1 Receiving operator characteristics curve showing the number of clinical 526 
indicators in relation to the presence of germline mutations in subjects with apparently 527 
sporadic PPGL 528 
 529 
 530 
Table 1: Genotype and phenotype of study subjects with germline mutations 531 
 532 
Table 2: Biochemical and tumour characteristics of study subjects 533 
 534 
Table 3: 535 
Comparison of clinical indicators by the presence of germline mutations in subjects 536 
with apparently sporadic phaeochromocytoma and paraganglioma 537 
 538 
 18 
Table 1: Genotype and phenotype of study subjects with germline mutations 539 
 540 
 541 
Gene Exon Mutation   Age at diagnosis Phenotype 542 
 543 
SDHB    2 NM_003000.2:c.112delC* #                      30  Recurrent metastatic bladder 544 
        paraganglioma 545 
 546 
SDHD    3 NM_003002.2:c.213_242dup           45  Head and neck paraganglioma 547 
  (p.Val72_Pro81dup)* 548 
 549 
RET    11 NM_020975.4:c.1902C>G #           38  Bilateral phaeochromocytomas 550 
  (p.Cys634Trp) 551 
 552 
    11 NM_020975.4:c.1900T>G           51  Bilateral phaeochromocytomas 553 
  (p.Cys634Gly) 554 
 555 
    11 NM_020975.4:c.1900T>C #           36  Bilateral phaeochromocytomas 556 
  (p.Cys634Arg) 557 
 558 
    11 NM_020975.4:c.1901G>A           39  Bilateral phaeochromocytomas 559 
  (p.Cys634Tyr) 560 
 561 
    11 NM_020975.4:c.1900T>C #           35  Bilateral phaeochromocytomas 562 
  (p.Cys634Arg) 563 
 564 
    16 NM_020975.4:c.2753T>C            25  Bilateral phaeochromocytomas 565 
  (p.Met918Thr) 566 
 567 
   11 NM_020975.4:c.1900T>C            28  Metastatic, bilateral  568 
  (p.Cys634Arg)     phaeochromocytomas 569 
      570 
NF1     - NA              49  Right phaeochromocytoma 571 
 572 
* Denotes novel mutations 573 
# Denotes subjects with apparently sporadic presentation 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
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Table 2: Biochemical and tumour characteristics of subjects with apparently sporadic 587 
phaeochromocytoma and paraganglioma 588 
 589 
 590 
Baseline parameters    Frequency  Percentage (%) 591 
 592 
 593 
Biochemical characteristics 594 
 595 
     Elevated 24-hour urine catecholamines  596 
     or fractionated metanephrine or VMA* 597 
           Yes           29                                93.5 598 
           No            2             6.5 599 
 600 
Tumour characteristics 601 
 602 
     Size of primary tumour  603 
     (Largest dimension in cm) 604 
           <1cm             0                0 605 
           1-3cm            8            22.9 606 
           3-6cm            20           57.1 607 
           >6cm            7           20.0 608 
 609 
     MIBG avidity# 610 
           MIBG-avid           25            89.3 611 
           Non MIBG-avid          3            10.7 612 
 613 
     Bilateral or multifocal tumours        10            28.6 614 
 615 
     Malignant tumours           4           11.4 616 
 617 
     Recurrent tumours           8           22.9 618 
 619 
*Missing data in 4 subjects; #Missing data in 7 subjects 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
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Table 3: 631 
Comparison of clinical indicators by the presence of germline mutations in subjects 632 
with apparently sporadic phaeochromocytoma and paraganglioma 633 
 634 
         Subjects with apparently sporadic  635 
     phaeochromocytoma and paraganglioma 636 
        (N = 35) 637 
 638 
Clinical indicators   Mutation Mutation p-value  639 
___________________________ positive negative   640 
  641 
 642 
N     4 (11.4%) 31 (88.6%) - 643 
 644 
Age at diagnosis (Year)  32 ± 6  46 ± 13 0.023 645 
 646 
   At or younger than 45 years old 4 (100%) 13 (42%) 0.045 647 
   Older than 45 years old  0 (0%)  18 (58%)  648 
 649 
Extra-adrenal disease   1 (25%) 7 (23%) 1.000 650 
 651 
Bilateral or multifocal tumours 4 (100%) 6 (19%) 0.004 652 
 653 
Malignant tumours   1 (25%) 3 (10%) 0.399 654 
 655 
Recurrence    2 (50%) 6 (19%) 0.218 656 
 657 
__________________________________________________________________ 658 
Statistically significance with p-value <0.05 were underlined and bolded 659 
Data are expressed as mean ± SD or median with inter-quartile range whichever is 660 
appropriate 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
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Figure 1 Receiving operator characteristics curve showing the number of clinical 673 
indicators in relation to the presence of germline mutations in subjects with apparently 674 
sporadic PPGL 675 
 676 
